BCAB vs. BDTX, GNFT, CADL, CRBU, IPSC, MGX, ZURA, ELEV, IVVD, and CHRS
Should you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Black Diamond Therapeutics (BDTX), Genfit (GNFT), Candel Therapeutics (CADL), Caribou Biosciences (CRBU), Century Therapeutics (IPSC), Metagenomi (MGX), Zura Bio (ZURA), Elevation Oncology (ELEV), Invivyd (IVVD), and Coherus BioSciences (CHRS). These companies are all part of the "biological products, except diagnostic" industry.
Black Diamond Therapeutics (NASDAQ:BDTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.
Black Diamond Therapeutics has higher earnings, but lower revenue than BioAtla. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.
BioAtla's return on equity of -72.94% beat Black Diamond Therapeutics' return on equity.
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 11.5% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Black Diamond Therapeutics received 15 more outperform votes than BioAtla when rated by MarketBeat users. However, 68.57% of users gave BioAtla an outperform vote while only 63.93% of users gave Black Diamond Therapeutics an outperform vote.
In the previous week, Black Diamond Therapeutics had 1 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 2 mentions for BioAtla. Black Diamond Therapeutics' average media sentiment score of 0.74 beat BioAtla's score of 0.64 indicating that BioAtla is being referred to more favorably in the news media.
Black Diamond Therapeutics has a beta of 2.56, indicating that its share price is 156% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.
Black Diamond Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 151.05%. BioAtla has a consensus price target of $8.67, indicating a potential upside of 473.95%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe BioAtla is more favorable than Black Diamond Therapeutics.
Summary
Black Diamond Therapeutics beats BioAtla on 9 of the 15 factors compared between the two stocks.
Get BioAtla News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
